Patents by Inventor Wang Yong
Wang Yong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240163943Abstract: A multilink access point may communicate with a legacy device. The multilink access point identifies an attempt, by at least one legacy station, to connect to the access point, determines that the at least one legacy station does not support multilink communications, broadcasts a beacon identifying information for a basic communication link that can be used by the at least one legacy station and associates with the at least one legacy station based at least on information included in the beacon, wherein the at least one legacy station communicates exclusively on the basic communication link with the access point.Type: ApplicationFiled: January 17, 2024Publication date: May 16, 2024Inventors: Jinjing JIANG, Jarkko L. KNECKT, Lochan VERMA, Qi WANG, Su Khiong YONG, Tianyu WU, Yong LIU
-
Patent number: 11984984Abstract: An electronic device that communicates frames is described. During operation, the electronic device may transmit the frames addressed to a recipient electronic device and associated with multiple links between the electronic device and the recipient electronic device. Then, the electronic device may receive block acknowledgments for at least a subset of the frames, where a given block acknowledgment is associated with the recipient electronic device and indicates received frames on a given link in the links. Moreover, the electronic device may control an amount of traffic conveyed on the links based at least in part on the block acknowledgments. Next, the electronic device may store a remainder of the frames based at least in part on the block acknowledgments, where the frames include the subset of the frames and the remainder of the frames. Note that the frames may have a common traffic identifier.Type: GrantFiled: December 19, 2022Date of Patent: May 14, 2024Assignee: Apple Inc.Inventors: Jarkko L Kneckt, Jinjing Jiang, Qi Wang, Su Khiong Yong, Tianyu Wu, Yong Liu
-
Publication number: 20240110410Abstract: A lock mechanism with an ice breaking mechanism. The lock mechanism is composed of a lock ring, an engagement plate, a pawl, a shaft, an engagement plate driving rod, a pawl release lever, a release lever, a support, a swinging claw, a tensioning wheel, a cable, a pulley, a limiting member, a supporting arm, a fixed shaft, a pull rod, a spring, a swinging ice breaking arm, an ice breaking pull rod, and the like. The lock mechanism is provided with the ice breaking mechanism. The ice breaking mechanism may be started to push a vehicle door away by a specific distance, so as to assist in manually or automatically opening the door, which improves the degree of satisfaction of customers.Type: ApplicationFiled: November 14, 2022Publication date: April 4, 2024Inventors: Hua YONG, Xiao YAO, Huang XINRAN, Wang YANGFEI
-
Patent number: 11917540Abstract: Some embodiments of this disclosure include apparatuses and methods for implementing a target wake time (TWT) technique for multicast communication. For example, some embodiments relate to a method including configuring a target wake time (TWT) process for delivering one or more multicast packets to a group of electronic devices. The method further includes determining that a service period associated with the TWT process has started and transmitting, in accordance with the TWT process, the one or more multicast packets during the service period, where the one or more transmitted multicast packets are addressed to the group of electronic devices.Type: GrantFiled: May 6, 2019Date of Patent: February 27, 2024Assignee: Apple Inc.Inventors: Jarkko L. Kneckt, Christiaan A. Hartman, Qi Wang, Su Khiong Yong, Yong Liu
-
Publication number: 20220106077Abstract: A device used to display a consumer product, which are referred to herein as a hang tab (102). More specifically, to eco-friendly hang tabs (102) made of biodegradable, degradable, and/or recyclable materials that can be used to display consumer products.Type: ApplicationFiled: January 19, 2020Publication date: April 7, 2022Inventors: Adam Christopher SCHETTLE, Wang YONG
-
Patent number: 10362071Abstract: A method, computer program product, and computer system for launching a collaboration session between a plurality of participants. Use data associated with the collaboration session may be identified. One or more collaboration services may be pre-provisioned with the collaboration session based upon, at least in part, the use data.Type: GrantFiled: November 2, 2016Date of Patent: July 23, 2019Assignee: International Business Machines CorporationInventors: Jonathan Dunne, Liam Harpur, Shao Hua, Wang Yong
-
Publication number: 20180267028Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.Type: ApplicationFiled: March 8, 2018Publication date: September 20, 2018Inventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
-
Patent number: 10011598Abstract: The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp.Type: GrantFiled: January 23, 2017Date of Patent: July 3, 2018Assignee: The Scripps Research InstituteInventors: Matthew D. Disney, Biao Liu, Jessica L. Childs-Disney, Wang-Yong Yang
-
Publication number: 20180124135Abstract: A method, computer program product, and computer system for launching a collaboration session between a plurality of participants. Use data associated with the collaboration session may be identified. One or more collaboration services may be pre-provisioned with the collaboration session based upon, at least in part, the use data.Type: ApplicationFiled: November 2, 2016Publication date: May 3, 2018Inventors: Jonathan Dunne, Liam Harpur, Shao Hua, Wang Yong
-
Patent number: 9933419Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.Type: GrantFiled: February 8, 2017Date of Patent: April 3, 2018Assignee: The Scripps Research InstituteInventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
-
Publication number: 20170234859Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.Type: ApplicationFiled: February 8, 2017Publication date: August 17, 2017Inventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
-
Publication number: 20170152261Abstract: The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically. 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp.Type: ApplicationFiled: January 23, 2017Publication date: June 1, 2017Inventors: Matthew D. Disney, Biao Liu, Jessica L. Childs-Disney, Wang-Yong Yang
-
Patent number: 9586944Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.Type: GrantFiled: July 15, 2014Date of Patent: March 7, 2017Assignee: The Scripps Research InstituteInventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
-
Patent number: 9550769Abstract: The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp.Type: GrantFiled: August 30, 2013Date of Patent: January 24, 2017Assignee: The Scripps Research InstituteInventors: Matthew D. Disney, Biao Liu, Jessica L. Childs-Disney, Wang-Yong Yang
-
Publication number: 20160257669Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.Type: ApplicationFiled: July 15, 2014Publication date: September 8, 2016Inventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
-
Publication number: 20150307487Abstract: The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5?CG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp.Type: ApplicationFiled: August 30, 2013Publication date: October 29, 2015Inventors: Matthew D. Disney, Biao Liu, Jessica L. Childs-Disney, Wang-Yong Yang
-
Patent number: 8927728Abstract: Photoreactive DNA cleaving conjugate compounds are provided comprising a DNA cleaving moiety which comprises an aryl alkyne group and a polyfunctional pH-regulated DNA-binding moiety which comprises at least one or two amino groups.Type: GrantFiled: May 7, 2012Date of Patent: January 6, 2015Assignee: The Florida State University Research Foundation, Inc.Inventors: Igor Alabugin, Wang-Yong Yang, Saumya Roy, Kemal Kaya, Qing-Xiang Sang
-
Patent number: 8334403Abstract: Compounds and methods for double-stranded DNA cleavage of light-activated lysine conjugates are enhanced at the slightly acidic pH suitable for selective targeting of cancer cells by the presence of two amino groups of different basicities. The first amino group plays an auxiliary role enhancing solubility and affinity to DNA whereas the second amino group which is positioned next to the light-activated DNA-cleaver undergoes protonation at the desired pH threshold. Protonation results in two synergetic effects which account for the increased DNA-cleaving ability at the lower pH: tighter binding to DNA at the lower pH; and the unproductive pathway which quenches the excited state of the photocleaver through intramolecular electron transfer is eliminated once the donor amino group next to the chromophore is protonated. The utility of these molecules for phototherapy of cancer is confirmed by the drastic increase in toxicity of five conjugates against cancer cell lines upon photoactivation.Type: GrantFiled: December 17, 2009Date of Patent: December 18, 2012Assignee: Florida State University Research Foundation, Inc.Inventors: Igor Alabugin, Serguei Kovalenko, Wang Yong Yang, Kerry Gilmore, Boris Breiner
-
Publication number: 20120288940Abstract: Photoreactive DNA cleaving conjugate compounds are provided comprising a DNA cleaving moiety which comprises an aryl alkyne group and a polyfunctional pH-regulated DNA-binding moiety which comprises at least one or two amino groups.Type: ApplicationFiled: May 7, 2012Publication date: November 15, 2012Applicant: The Florida State University Research Foundation, Inc.Inventors: Igor Alabugin, Wang-Yong Yang, Saumya Roy, Kemal Kaya, Qing-Xiang Sang
-
Patent number: D734783Type: GrantFiled: May 7, 2013Date of Patent: July 21, 2015Assignee: MANITOWOC FOODSERVICE COMPANIES, LLCInventors: Wang Yong, Wen Yongle, Sun Zhi Qiang, Zhu Ai Hua